Deregulation of the CDKN2A-CCND-CDK4/6-retinoblastoma 1 (Rb) pathway is frequently observed in about 25% of unselected sarcomas and is a distinct pathogenic characteristic for specific subtypes. This evidence concerns the gene CDKN2A and sarcoma.